• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Adagene Inc.

    2/11/22 3:26:06 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email
    SC 13G 1 eh220223350_13g-adagene.htm SCHEDULE 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Adagene Inc.

    (Name of Issuer)
     

    Ordinary shares, par value US$0.0001 per share

    (Title of Class of Securities)
     

    005329107**

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **This CUSIP applies to the American Depositary Shares, evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares. No CUSIP has been assigned to the ordinary shares.

     

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 2 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Singapore Fund Pte. Ltd.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Singapore

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 3 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Singapore Interholdco Ltd.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 4 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Bermuda) IV, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 5 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Bermuda) EU, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 6 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar (Bermuda), L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 7 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP (Bermuda) L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 8 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 9 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments III, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 10 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments IV, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 11 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments V, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 12 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments CDA, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 13 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Lux) SCSp

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 14 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar (Lux) SCSp

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 15 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic (Lux) S.à r.l.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 16 of 25

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Singapore AI Pte. Ltd.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Singapore

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,782,441

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,782,441

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,782,441

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.8%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 17 of 25

     

     

    ITEM 1. (a) Name of Issuer
         
     

    Adagene Inc.

         
      (b) Address of Issuer’s Principal Executive Offices
         
     

    4F, Building C14, No. 218,
    Xinghu Street, Suzhou Industrial Park
    Suzhou, Jiangsu Province, 215123
    People's Republic of China

       
    ITEM 2. (a) Name of PersonS Filing
         
     

    This statement is being filed on behalf of each of the following persons (collectively, the “Reporting Persons”).

         
      (i) General Atlantic Singapore Fund Pte. Ltd. (“GASF”);
         
      (ii) General Atlantic Singapore Interholdco Ltd. (“GAS Interholdco”);
         
      (iii) General Atlantic Partners (Bermuda) IV, L.P. (“GAP Bermuda IV”);
         
      (iv) General Atlantic Partners (Bermuda) EU, L.P. (“GAP Bermuda EU”);
         
      (v) General Atlantic GenPar (Bermuda), L.P. (“GenPar Bermuda”);
         
      (vi) GAP (Bermuda) L.P. (“GAP (Bermuda) LP”);
         
      (vii) General Atlantic, L.P. (“GA LP”);
         
      (viii) GAP Coinvestments III, LLC (“GAPCO III”);
         
      (ix) GAP Coinvestments IV, LLC (“GAPCO IV”);
         
      (x) GAP Coinvestments V, LLC (“GAPCO V”);
         
      (xi) GAP Coinvestments CDA, L.P. (“GAPCO CDA”);
         
      (xii) General Atlantic Partners (Lux) SCSp (“GAP Lux”);
         
      (xiii) General Atlantic GenPar, (Lux) SCSp (“GA GenPar Lux”);
         
      (xiv) General Atlantic (Lux) S.à. r.l. (“GA Lux”); and
         
      (xv) General Atlantic Singapore AI Pte. Ltd. (“GA AI”).
       
      GAP Bermuda IV, GAP Bermuda EU, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA are collectively referred to as the “GA Funds.”

     

     

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 18 of 25

     

     

      (b) Address of Principal Business Office, or if none, Residence
         
     

    The address of GA LP, GAPCO III, GAPCO IV, GAPCO V, and GAPCO CDA is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The address of GAS Interholdco, GAP Bermuda IV, GAP Bermuda EU, GenPar Bermuda, and GAP (Bermuda) LP is C/O Conyers Client Services Limited, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of GAP Lux, GA GenPar Lux and GA Lux Sarl is 412F, route d’Esch, L-2086 Luxembourg, Grand Duchy of Luxembourg. The address of GASF and GA AI is 80 Robinson Road #02-00, Singapore, 068898.

         
      (c) Citizenship
         
      (i) GASF - Singapore
         
      (ii) GAS Interholdco - Bermuda
         
      (iii) GAP Bermuda IV - Bermuda
         
      (iv) GAP Bermuda EU - Bermuda
         
      (v) GenPar Bermuda - Bermuda
         
      (vi) GAP (Bermuda) LP - Bermuda
         
      (vii) GA LLC - Delaware
         
      (viii) GAPCO III - Delaware
         
      (ix) GAPCO IV - Delaware
         
      (x) GAPCO V - Delaware
         
      (xi) GAPCO CDA - Delaware
         
      (xii) GAP Lux - Luxembourg
         
      (xiii) GA GenPar Lux - Luxembourg
         
      (xiv) GA Lux - Luxembourg
         
      (xv) GA AI - Singapore

     

     

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 19 of 25

     

     

      (d) Title of Class of Securities
         
     

    Ordinary shares, par value US$0.0001 per share (“ordinary shares”).

     

    The Issuer’s American Depositary Shares (the “ADSs”), evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares, are listed on the Nasdaq Global Select Market under the symbol “ADAG.”

         
      (e) CUSIP Number
         
     

    005329107*

    *This CUSIP applies to the ADSs, evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares. No CUSIP has been assigned to the ordinary shares.

         
    ITEM 3.

    IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS:

         
      Not Applicable.
       
    ITEM 4.

    OWNERSHIP

       
      As of December 31, 2021, the Reporting Persons owned the following number of ordinary shares:

     

      (i) GASF owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (ii) GAS Interholdco owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (iii) GAP Bermuda IV owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (iv) GAP Bermuda EU owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (v) GenPar Bermuda owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (vi) GAP (Bermuda) LP owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (vii) GA LP owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (viii) GAPCO III owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.

     

     

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 20 of 25

     

     

      (ix) GAPCO IV owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (x) GAPCO V owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (xi) GAPCO CDA owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (xii) GAP Lux owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (xiii) GA GenPar Lux owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (xiv) GA Lux owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
         
      (xv) GA AI owned of record 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares, or approximately 8.8% of the issued and outstanding ordinary shares.

     

     

    GA AI is wholly owned by GASF. The majority shareholder of GASF is GAS Interholdco. The members of GAS Interholdco that share beneficial ownership of the ordinary shares and ADSs held of record by GA AI are the GA Funds. The general partner of GAP Lux is GA GenPar Lux and the general partner of GA GenPar Lux is GA Lux. The general partner of GAP Bermuda EU and GAP Bermuda IV and the sole shareholder of GA Lux is GenPar Bermuda. GAP (Bermuda) LP, which is controlled by the Management Committee of GASC MGP, LLC (the “GA Management Committee”), is the general partner of GenPar Bermuda. GA LP, which is also controlled by the GA Management Committee, is the managing member of GAPCO III, GAPCO IV and GAPCO V and the general partner of GAPCO CDA. There are nine members of the GA Management Committee as of the date hereof. Each of the members of the GA Management Committee disclaims ownership of the ordinary shares, the ADSs and the underlying ordinary shares except to the extent that he has a pecuniary interest therein. The name, the business address and the citizenship of each of the members of the GA Management Committee and the directors of GASF and GAS Interholdco, in each case as of the date hereof, is attached hereto as Schedule A and is hereby incorporated by reference.

     

    Amount Beneficially Owned:

    By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares.

     

    Percentage Owned:

    All calculations of percentage ownership herein are based on an aggregate of 54,397,383 ordinary shares of the Issuer reported to be outstanding as of March 31, 2021, as reflected in the Issuer’s Annual Report on Form 20-K, filed with the U.S. Securities and Exchange Commission on April 28, 2021.

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 21 of 25

     

     

      Number of Shares as to Which Such Person Has Sole/Shared Power to Vote or to Direct the Vote and Sole/Shared Power to Dispose or to Direct the Disposition of:
      (i) Each of the Reporting Persons may be deemed to have the sole power to direct the voting and dispositions of the ordinary shares, the ADSs and underlying ordinary shares as indicated on such Reporting Person’s cover page included herein.
         
      (ii) Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares that may be deemed to be owned beneficially by each of them.

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not Applicable.
       
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      Not Applicable.
       
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
       
      Not Applicable.
       
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
     

    See Item 4, which states the identity of the members of the group filing this Schedule 13G.

       
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not Applicable.
       
    ITEM 10. CERTIFICATION
       
      Not Applicable.

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 22 of 25

     

     

    Exhibit Index

     

    Exhibit 1: Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 23 of 25

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 11, 2022

     

      GENERAL ATLANTIC SINGAPORE FUND PTE. LTD.  
           
      By: /s/ Ong Yu Huat  
      Name: Ong Yu Huat  
      Title: Director  
           
         
      GENERAL ATLANTIC SINGAPORE INTERHOLDCO LTD.  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Director  
           
         
      GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.  
         
     

    By:

    General Atlantic GenPar (Bermuda), L.P., its General Partner

     
         
     

    By:

    GAP (Bermuda) L.P., its General Partner

     
         
      By: GAP (Bermuda) GP Limited, its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.  
         
     

    By:

    General Atlantic GenPar (Bermuda), L.P., its General Partner

     
         
     

    By:

    GAP (Bermuda) L.P., its General Partner

     
         
      By: GAP (Bermuda) GP Limited, its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
           
      GENERAL ATLANTIC GENPAR (BERMUDA), L.P.  
         
     

    By:

    GAP (Bermuda) L.P., its General Partner

     
         
      By: GAP (Bermuda) GP Limited, its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP (BERMUDA) L.P.  
           
     

    By:

    GAP (Bermuda) GP Limited, its general partner

     
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  

     

      

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 24 of 25

     

     

      GENERAL ATLANTIC, L.P.  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS III, LLC  
         
      By: General Atlantic, L.P., its Managing Member  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS IV, LLC  
         
      By: General Atlantic, L.P., its Managing Member  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS V, LLC  
         
      By: General Atlantic, L.P., its Managing Member  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS CDA, L.P.  
         
      By: General Atlantic, L.P., its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  

     

     

     

     

    CUSIP No. 005329107 SCHEDULE 13G Page 25 of 25

     

     

      GENERAL ATLANTIC PARTNERS (LUX) SCSP  
         
     

    By:

    General Atlantic GenPar (Lux) SCSp, its General Partner

     
           
      By: General Atlantic (Lux) S.à r.l., its General Partner  
           
      By: /s/ Ingrid van der Hoorn  
      Name: Ingrid van der Hoorn  
      Title: Manager A  
           
      By: /s/ Gregor Dalrymple  
      Name: Gregor Dalrymple  
      Title: Manager B  
         
         
      GENERAL ATLANTIC GENPAR, (LUX) SCSP  
         
      By: General Atlantic (Lux) S.à. r.l., its General Partner  
           
      By: /s/ Ingrid van der Hoorn  
      Name: Ingrid van der Hoorn  
      Title: Manager A  
           
      By: /s/ Gregor Dalrymple  
      Name: Gregor Dalrymple  
      Title: Manager B  
         
         
      GENERAL ATLANTIC (LUX) S.À R.L.  
         
      By: /s/ Ingrid van der Hoorn  
      Name: Ingrid van der Hoorn  
      Title: Manager A  
           
      By: /s/ Gregor Dalrymple  
      Name: Gregor Dalrymple  
      Title: Manager B  
         
         
      GENERAL ATLANTIC SINGAPORE AI PTE. LTD.  
         
      By: /s/ Ong Yu Huat  
      Name: Ong Yu Huat  
      Title: Director  

     

      

     

     

    SCHEDULE A

    Members of the GA Management Committee (as of the date hereof)

    Name Address Citizenship

    William E. Ford

    (Chief Executive Officer)

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Gabriel Caillaux

    23 Savile Row

    London W1S 2ET

    United Kingdom

    France
    Andrew Crawford

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Martin Escobari

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    Bolivia and Brazil
    Anton J. Levy

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Sandeep Naik

    Asia Square Tower 1

    8 Marina View, #41-04

    Singapore 018960

    United States
    Graves Tompkins

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    N. Robbert Vorhoff

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Eric Zhang

    Suite 5704-5706, 57F

    Two IFC, 8 Finance Street

    Central, Hong Kong, China

    Hong Kong SAR

     

     

     

     

    Directors of General Atlantic Singapore Fund Pte. Ltd.

    (as of the date hereof)

    Name Address Citizenship
    Ong Yu Huat

    Asia Square Tower 1

    8 Marina View, #41-04

    Singapore 018960

    Singapore

    Izkander Edward Heylett

    Asia Square Tower 1

    8 Marina View, #41-04

    Singapore 018960

    Malaysia

     

    Directors of General Atlantic Singapore Interholdco Ltd.

    (as of the date hereof)

    Name Address Citizenship
    Michael Gosk

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Christopher G. Lanning

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States

     

     

     

     

    EXHIBIT 1

     

    JOINT ACQUISITION STATEMENT

    PURSUANT TO RULE 13D-1(k)(1)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is accurate.

     

    February 11, 2022

     

      GENERAL ATLANTIC SINGAPORE FUND PTE. LTD.  
           
      By: /s/ Ong Yu Huat  
      Name: Ong Yu Huat  
      Title: Director  
           
         
      GENERAL ATLANTIC SINGAPORE INTERHOLDCO LTD.  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Director  
           
         
      GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.  
         
     

    By:

    General Atlantic GenPar (Bermuda), L.P., its General Partner

     
           
     

    By:

    GAP (Bermuda) L.P., its General Partner

     
           
      By: GAP (Bermuda) GP Limited, its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  

     

     

     

     

      GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.  
         
     

    By:

    General Atlantic GenPar (Bermuda), L.P., its General Partner

     
         
      By: GAP (Bermuda) L.P., its General Partner  
         
     

    By:

    GAP (Bermuda) GP Limited, its General Partner

     
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
           
      GENERAL ATLANTIC GENPAR (BERMUDA), L.P.  
         
     

    By:

    GAP (Bermuda) L.P., its General Partner

     
         
      By: GAP (Bermuda) GP Limited, its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP (BERMUDA) L.P.  
           
     

    By:

    GAP (Bermuda) GP Limited, its General Partner

     
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GENERAL ATLANTIC, L.P.  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  

     

     

     

     

     

      GAP COINVESTMENTS III, LLC  
         
      By: General Atlantic L.P., its Managing Member  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS IV, LLC  
         
      By: General Atlantic, L.P., its Managing Member  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS V, LLC  
         
      By: General Atlantic, L.P., its Managing Member  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  
           
         
      GAP COINVESTMENTS CDA, L.P.  
         
      By: General Atlantic, L.P., its General Partner  
           
      By: /s/ Michael Gosk  
      Name: Michael Gosk  
      Title: Managing Director  

     

     

     

     

      GENERAL ATLANTIC PARTNERS (LUX) SCSP  
         
     

    By:

    General Atlantic GenPar (Lux) SCSp, its General Partner

     
         
      By: General Atlantic (Lux) S.à r.l., its General Partner  
           
      By: /s/ Ingrid van der Hoorn  
      Name: Ingrid van der Hoorn  
      Title: Manager A  
           
      By: /s/ Gregor Dalrymple  
      Name: Gregor Dalrymple  
      Title: Manager B  
         
         
      GENERAL ATLANTIC GENPAR, (LUX) SCSP  
         
      By: General Atlantic (Lux) S.à. r.l., its General Partner  
           
      By: /s/ Ingrid van der Hoorn  
      Name: Ingrid van der Hoorn  
      Title: Manager A  
           
      By: /s/ Gregor Dalrymple  
      Name: Gregor Dalrymple  
      Title: Manager B  
         
         
      GENERAL ATLANTIC (LUX) S.À R.L.  
         
      By: /s/ Ingrid van der Hoorn  
      Name: Ingrid van der Hoorn  
      Title: Manager A  
           
      By: /s/ Gregor Dalrymple  
      Name: Gregor Dalrymple  
      Title:

    Manager B

     
         
         
      GENERAL ATLANTIC SINGAPORE AI PTE. LTD.  
         
      By: /s/ Ong Yu Huat  
      Name: Ong Yu Huat  
      Title: Director  

     

     

     

    Get the next $ADAG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    SEC Filings

    See more
    • Amendment: SEC Form F-3/A filed by Adagene Inc.

      F-3/A - Adagene Inc. (0001818838) (Filer)

      5/23/25 4:06:11 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Adagene Inc.

      6-K - Adagene Inc. (0001818838) (Filer)

      5/22/25 5:05:23 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

      SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

      5/15/25 5:29:08 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Financials

    Live finance-specific insights

    See more
    • Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

      – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

      8/30/22 5:25:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

      CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for over forty weeks Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months and only 1 out of 41 patients was censored due to early withdrawal within the first 12 months SAN DIEGO and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company

      5/22/25 5:05:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

      - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

      4/28/25 8:00:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

      SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3. Abstract Title: Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRCDate: Saturday, May 31, 2025Poster Viewing: 9:00 AM-12:00 PM CDTOnsite Location: McCormick Place, Chicago, IL, Board #248Abstract Number: 3579 Poster will be made available on the Publications page of the company's website here. About AdageneAdagene

      4/23/25 10:05:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Leadership Updates

    Live Leadership Updates

    See more
    • Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

      - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

      4/28/25 8:00:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

      - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

      3/7/24 4:01:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

      - Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene's novel anti-CTLA-4 therapies delivered systemically at higher and repeated doses with compelling safety - SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) --  Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the "SAB"). Professor Marabelle is a physician-scientist with expertise in oncology and imm

      3/5/23 7:39:30 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adagene Inc.

      SC 13G/A - Adagene Inc. (0001818838) (Subject)

      11/7/24 4:32:13 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

      SC 13D/A - Adagene Inc. (0001818838) (Subject)

      3/1/24 4:30:20 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Adagene Inc. (Amendment)

      SC 13G/A - Adagene Inc. (0001818838) (Subject)

      2/9/24 8:35:54 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adagene downgraded by Morgan Stanley

      Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

      1/31/25 8:29:36 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Adagene with a new price target

      Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously

      2/1/22 9:41:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care